Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Upifitamab Rilsodotin (XMT 1536) as Post Platinum Maintenance Therapy for Participants with Recurrent, Platinum Sensitive Ovarian Cancer (UP NEXT)
NCT Number:
NCT05329545
Phase:
III
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Ovary
Study Objectives:
Study Documents
(MUSC NetID required for document access)